Lipids & metabolic liver disease
End-stage renal diseases associated with SGLT2 inhibitors versus GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease
Authors' conclusion
The use of SGLT2i was associated with lower risk of ESRD compared to GLP-1RA in MASLD. The protective association was presented regardless of CKD status.
Study context
- Population
- Patients with MASLD initiating SGLT2 inhibitors (SGLT2i) or GLP-1 RA, Korea nationwide healthcare claims 2014–2023Propensity score (PS)-matched pairs: 1,268 with chronic kidney disease (CKD)
- Participants
- 333,082 patients
- Exposure
- SGLT2i vs GLP-1 RA
- Outcome
- Composite of end-stage renal diseases (ESRD)
Methodological detailsnationwide healthcare claims, new-user design, 1:1 propensity-score matched, stratified by baseline CKD status
- Nationwide healthcare claims
- New-user design
- 1:1 propensity-score matched
- Stratified by baseline CKD status
Main finding
As reported in the abstract
ESRD
SGLT2i vs GLP-1RAHazard ratio (95% CI)
Cohort with CKD; 20.3vs 30.0 events per 1,000 person-years; 33% lower risk
0.67(0.45–1.00)
Cohort without CKD; 0.9vs 2.5 events per 1,000 person-years; 68% lowered risk
0.32(0.19–0.53)
Observational data: associations, not effects.
Original publication
End-stage renal diseases associated with SGLT2 inhibitors versus GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease. Diabetes Res Clin Pract. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →